E-POSTER PRESENTATION INSTRUCTIONS
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
E-POSTER PRESENTATION INSTRUCTIONS
The abstract review committee tries to accommodate submitters preferred presentation format. However, PLEASE BE AWARE THAT THE
ABSTRACT COMMITTEE RESERVES THE RIGHT TO SELECT THE FINAL PRESENTATION FORMAT FOR ALL SUBMITTED ABSTRACTS IN ORDER TO
MEET THE NEEDS OF CONFERENCE PLANNING.
E-Poster presentations will take place on the AMMI Canada – CACMID Conference platform beginning on Sunday, April 25th, 2021. Presentation
will be available to view on the platform until Sunday, May 30, 2021. Conference delegates will have the ability to interact with poster
presenters via a chat function within the platform. You will be required to monitor the chat on your poster a minimum of once a day for the
duration of the live conference by logging into the Conference Platform as a delegate. Please include an email on your poster where delegates
can reach you for questions following the live days.
E-posters have the option of presenting either as single page PDF poster with no narration or a narrated PowerPoint. Important: This does not
apply to Competing Student Posters which must be presented as a single page poster with no narration. If you also have a Student Poster
accepted please see the 2021 Student Poster Schedule & Presentation Instructions.
Examples:
I. E-poster Single Page PDF Poster-no narration
II. E-poster Multiple Slide, narrated PowerPoint (downloadable file)
Narrated e-poster presentations should be submitted as a PowerPoint using a 16:9 ratio.
1. Open PowerPoint on your PC or Mac.
2. From the top menu, (depending on the version of PowerPoint you have) select Design, then Page Setup OR File, then Page Setup, and
change Slides sized for to: On-screen Show (16:9).
3. Click OK.
Pre-recording audio: Instructions for adding audio to a Powerpoint presentation
If you have any trouble converting your presentation to 16:9 or adding audio please contact meetings@ammi.ca for assistance.
Presenters are required to submit their presentations via Drop Box no later than March 31st, 2021. Please upload your presentation using your
Session Code and Presentation Title as the file name (Ex. P01- Prevalence and clinical correlation of indeterminate Clostridium difficile tests
utilizing a 2-step algorithm If changes need to be made to a presentation a new file must be uploaded to the Dropbox link, please add Version
2,3,4 and so on to the end of your title to indicate it is replacing an already submitted presentation. Changes can be made to your presentation
until March 31st, 2021. You can submit your presentation here.
IMPORTANT
• All presenting authors MUST be registered for the annual conference no later than Wednesday, March 31st, 2021. If registration is not
complete by this date, the abstract will be REMOVED and will NOT be published. Click Here to Register.• All presentations must be uploaded to the Drop Box Link by March 31st, 2021.
• Should you need assistance or clarification please contact meetings@ammi.ca or call 1-866-467-1215 ext 103
2021 E-poster Presentation Schedule
Session Abstract
Abstract Title Presenter
Code ID
P01 Investigating the Efficacy of Insecticide-treated Window Screens and Eaves against Anopheles Beverly Anaele 10
Mosquitoes
P02 Outcomes of a Risk-Based Decision-Making Process for Reducing the Risk of Hepatitis E Virus Steven Drews 14
Transfusion Transmission via the Canadian Blood Supply
P03 Evaluation of the NG-Test Carba 5 Multiplex Immunochromatographic Assay and Cepheid Ghada Al-Rawahi 24
Xpert Carba-R Assay for the Detection of Carbapenemase Genes in Gram Negative Organisms
P04 SARS-CoV-2 transmission through cells, tissues and organs transplantation Amaury Gaussen 25
P05 One Health genomic study of extended spectrum beta-lactamases (ESBL)-producing Amrita Bharat 26
Salmonella enterica in Canada, 2012-2016
P06 Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive David Claveau 34
aspergillosis and mucormycosis
P07 A virtual care model utilizing patient directed oximetry monitoring for outpatients with Megan Devlin 35
COVID-19: A quality improvement study
P08 Case report: Actinotignum schaalii identified in a neck abscess of a pediatric patient Ruwandi 38
Kariyawasam
P09 Synergistic activity of combinations of colistin with other antibiotics against multidrug- and Tatiana 42
extensively drugresistant clinical isolates of Klebsiella pneumoniae, Acinetobacter baumannii Petrovskaya
and Pseudomonas aeruginosa
P10 The vancomycin minimum inhibitory concentration of Staphylococcus species isolated from Eugene Yeung 43
children's blood culture
P11 Microbiological efficiency of the combinations of two carbapenems against Klebsiella Elena Timoskova 45
pneumoniae carbapenemase-producing strains
P12 Waning anti-SARS-CoV2-2 plaque reduction neutralization test titers in repeat Canadian Steven Drews 48
convalescent plasma donors: April-December 2020.Session Abstract
Abstract Title Presenter
Code ID
P13 Impact of the COVID-19 pandemic on the incidence and serotype distribution of invasive Allison McGeer 51
pneumococcal disease in south-central Ontario
P14 Impact of an antimicrobial stewardship initiative to reduce asymptomatic bacteriuria in a Maggie Wong 53
tertiary hospital
P15 Development of quality indicators to evaluate appropriate empiric antimicrobial use in Emily Black 59
pediatric patients
P16 Penicillin Susceptibility in Staphylococcus aureus – An Opportunity for Antimicrobial Philippe 63
Stewardship? Lagacé-Wiens
P17 Nosocomial SARS-CoV-2 infection in healthcare workers (HCWs): descriptive analysis of a Devika Dixit 64
large acute care hospital COVID-19 outbreak on cardiac units.
P18 Verification of the Vitek® 2 N391 Gram-Negative AST Card - Results are Method-Dependent Philippe 65
Lagacé-Wiens
P19 Evaluation of the Solana® Influenza A and B Nucleic Acid Amplification Assay Philippe 66
Lagacé-Wiens
P20 Stepwise implementation of an antimicrobial stewardship prospective audit and feedback Justin Chen 68
intervention at a large academic centre in Canada
P21 SARS-CoV2 outbreak amongst physicians at a Canadian curling bonspiel: a descriptive Bonnie 71
observational study Meatherall
P22 Verification of 2019 CLSI M100 Revised Ciprofloxacin Breakpoints for Pseudomonas Philippe Lagacé- 72
aeruginosa using the Vitek® 2 N391 Gram-Negative AST Card Wiens
P23 Congenital SARS-CoV-2 infection in a pre-term neonate with viable virus from the placenta Joseph 75
Vayalumkal
P24 Comparative analysis of capillary versus venous blood for serologic detection of SARS-CoV-2 Tamara Pidduck 77
antibodies by rPOC lateral flow tests
P25 Cefiderocol therapy in a Canadian urban academic centre: A new option to treat Christine Ondro 78
carbapenem-resistant gram-negative infectionsSession Abstract
Abstract Title Presenter
Code ID
P26 Survey results from a pilot antimicrobial stewardship prospective audit and feedback in April Chan 79
general surgery
P27 Associated antibiotic use for community infections in British Columbia: a review of Ariana Saatchi 82
prescribing from 2000 – 2018.
P28 The impact of a reported beta-lactam allergy on cefazolin administration in surgical Holly Hoang 83
prophylaxis: cefazolin is still best, but is it given?
P29 A review of surgical antibiotic prophylaxis practice in adult urology procedures: opportunities Justin Chen 84
for antimicrobial stewardship collaboration
P30 Real-life experience with ceftobiprole in Canada: results from the CLEAR (Canadian George Zhanel 90
LEadership on Antimicrobial Real-life usage) Registry
P31 An examination of selection, timing and duration of surgical prophylaxis for vascular Holly Hoang 91
procedures at a major Canadian vascular surgery centre
P32 An audit of surgical antibiotic prophylaxis in orthopedic surgery with particular focus on Susan Fryters 93
duration of prophylaxis
P33 An assessment of surgical antibiotic prophylaxis practices at a Canadian tertiary pediatric Alena Tse-Chang 94
centre
P34 Comparison of contact precautions with routine practices for the prevention of vancomycin- Heather 95
resistant Enterococci(VRE) infections in hospitals: The secret is in the routine Glassman
P35 What’s in a number? The value of titres as routine proof of immune protection Natalie Marshall 103
P36 A case of multisystem inflammatory syndrome in adults (MIS-A): a rare manifestation of Teagan King 104
COVID-19
P37 Absence of Transmission of NDM and OXA-48-like Carbapenemase Genes in a Long-term Care Carl Boodman 112
Facility
P38 Sensitivity of Cobas® 68/8800 SARS-CoV-2 test using gargle specimens with two different Patrick Benoit 117
processing methods
P39 Evaluation of the Q Score for Assessing Wound Swab Quality in a Tertiary Care Centre Shawn Clark 118Session Abstract
Abstract Title Presenter
Code ID
P40 Susceptibility patterns for Enterococcus spp. clinical isolates collected over a 14-year period Victoria Bugaj 122
P41 Maternal and fetal infection of non-typhoidal Salmonella during pregnancy Xena Li 123
P42 Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR George Zhanel 129
(Canadian LEadership on Antimicrobial Real-life usage) Registry
P43 Risks factors for severe outcomes in patients hospitalized with COVID-19 in a network of Robyn Mitchell 141
Canadian acute-care hospitals
P44 Reliability of E-gene Cycle Threshold (Ct) Values in Interpreting Duration of COVID-19 William Stokes 143
Infection
P45 Susceptibility of Pseudomonas Aeruginosa to Empiric Therapy and alternative β-lactam Radwan El Ali 144
Antimicrobials in Intensive Care Unit Patients with Respiratory Tract Infections in Canadian
Centers: SMART Surveillance (2016-2019)
P46 Nasopharyngeal Expression of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Mohammad 145
Serine Protease 2 (TMPRSS2) in Children Compared to Adults Within Family Clusters Exposed Hasan
to COVID-19
P47 The association of frailty and outcomes among hospitalized COVID19 patients in Toronto Christopher 150
Kandel
P48 Real-life experience with IV fosfomycin in Canada: results from the CLEAR (Canadian George Zhanel 153
LEadership on Antimicrobial Real-life usage) Registry
P49 Antimicrobial resistance trends of Staphylococcus aureusisolates collected from patients over Dylan Bedi 156
14 years
P50 Limitations of statistical methods used to determine the vancomycin therapeutic range: A Bruce Dalton 157
data simulation experiment.
P51 Prescribing pattern of restricted antimicrobials at a quaternary care academic hospital Justin Chen 158
P52 A Quality Audit of Surgical Antibiotic Prophylaxis Timing, Redosing, and Post-Operative Dosing Lynora Saxinger 159
Practices in 5 Hospital Sites: The Devil is in the Details
P53 Targeted plasma metabolomics method for the diagnosis of acute SARS-CoV-2 Catherine Hogan 160Session Abstract
Abstract Title Presenter
Code ID
P54 Lineage distributions of SARS-CoV-2 during the second wave in British Columbia Kimia Kamelian 162
P55 Assessment of fungal ITS PCR performance in formalin-fixed paraffin-embedded tissues Shawn Clark 163
P56 Comparative genomics analysis of an IncR plasmid encoding blaNDM-1 from Enterobacter Florence 164
hormaechei involved in outbreak in Quebec. Doualla-Bell
P57 Y. regensburgei Infection in an Immunocompetent Host Fatimah 165
AlMutawa
P58 Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and Erin Carruthers 168
WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
P59 Necrotic myositis in an immunocompetent patient with persistent Bacillus cereus bacteremia Anna Cvetkovic 170
and acute liver failure: A Case Report
P60 How has antimicrobial use changed during the COVID-19 pandemic? A look at community Braden Knight 171
antimicrobial use in Canada
P61 Isolating Candida auris at Humber River Hospital: A Comparative Evaluation of Media to Chantal Morris 173
Develop a Screening Protocol for an Emerging Pathogen
P62 Comparison of the Sensititre CAN1MSTF panel and the BD Phoenix NMIC-450 panel for Lisa Li 174
susceptibility testing of multi-drug resistant gram negative organisms
P63 Community antibiotic use at the population level during the SARS-CoV2 pandemic in British Abdullah 175
Columbia, Canada Mamun
P64 Prospective audit and feedback (PAF) in level II neonatal intensive care units (NICU) – Is it Khaled Alsager 178
worth it?
P65 Validation of the triplex real-time RT-PCR assay for detection of Chikungunya, Dengue, and Min-Kuang Lee 179
Zika viruses
P66 Viral co-circulation during the COVID-19 pandemic: Broad respiratory testing to inform Natalie Marshall 180
diagnostic stewardship
P67 The Impact of ID Consultation in Patients with Enterococcus species Bloodstream Infection Brittany Kula 184Session Abstract
Abstract Title Presenter
Code ID
P68 Comparison of the BD Phoenix CPO Detect Test and the NG-Test® CARBA-5 lateral flow assay Lisa Li 185
for the detection of carbapenemase-producing organisms
P69 Performance of three different screening media for the detection of carbapenemase- Lisa Li 186
producing organisms
P70 Comparison of two commercial broth microdilution methods for testing susceptibility to Lisa Li 187
colistin in multi-drug resistant gram negative organisms
P71 An audit of surgical antibiotic prophylaxis in obstetrical/gynecological surgery Holly Hoang 190
P72 Using Propidium Monoazide in Real-Time Quantitative PCR to Distinguish Viable Verses Non- Melissa Glier 193
Viable Enteric Viruses in Water Samples
P73 Validation of gargle samples on the point-of-care cobas Liat for the detection of SARS-CoV-2 Judith Fafard 194
P74 Cohort study of children hospitalized with COVID-19 infection Joan Robinson 195
P75 Evaluation of the AllplexTM 2019-nCoV assay for the detection of SARS-CoV-2 in a variety of Shawn Clark 196
clinical matrices
P76 Analysis of the performance of water gargle samples for SARS-CoV-2 detection by RT-PCR in a Emilie Vallières 198
pediatric population
P77 Persistent Pandoraea sputorum bacteremia in a patient with extensive burns: a case report Victoria Weaver 200
P78 Validation of the EuroImmun Anti-SARS-CoV-2 ELISA Assay for Detection of IgG and IgA Shaista Anwer 201
Antibodies in Human Breast Milk
P79 Ct as an Indicator of SARS-CoV-2 WGS success Kimberley 203
Macdonald
P80 A Novel Laboratory Informatics System for COVID-19 Outbreak Response and Whole Genome Chris Fjell 204
Sequencing of Pathogens for Public Health in British Columbia
P81 Expediting QC for COVID WGS analysis via Dashboards Kimberley 205
Macdonald
P82 The Frequency of Carbapenemase-producing Enterobacterales During COVID-19 Shaista Anwer 206
P83 Realization of theoretical savings following implementation of bioMerieux’s VITEK® MS for Georgia Carr 207
rapid microbial identification in patients with blood stream infectionsP84 Human Herpes Virus-6 Surveillance in Hematopoietic Stem Cell Transplantation Patients Sara 211
Abolghasemi
P85 OPAT Quality Indicators at a Tertiary Care Centre Reveal Vast Room for Improvement. Evan Wilson 212
P86 Emergency Department Visits and Readmission Rates of Patients Discharged on OPAT: A Evan Wilson 213
Retrospective Observational Study to Identify PredictorsYou can also read
